Prof Robert Coleman speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about the current treatment standards for primary ovarian cancer.

He believes that in the last 6 years there has been a revolution in how we approach this disease due to the understanding of the BRCA mutations and how PARP inhibitors can demonstrate therapeutic efficacy.

Prof Coleman explains that this subsequently paved the way for more trials evaluating the use of more PARP inhibitors.